Drugs in Dev. Musculoskeletal
Phase II/ Phase III
Belgium 
Lead Product(s) : Hyaluronic Acid
Therapeutic Area : Musculoskeletal
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Two studies are the pivotal JTA-004 Ph III clinical study targeting osteoarthritic knee pain and Ph IIb study of its allogeneic cell therapy product, ALLOB, in difficult tibial fractures.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 23, 2020
Lead Product(s) : Hyaluronic Acid
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : JTA-004
Therapeutic Area : Musculoskeletal
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study on Visco-antalgic Intra-articular Administration in Symptomatic Knee Osteoarthritis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 15, 2016
Lead Product(s) : JTA-004
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Autologous Osteoblastic Cell
Therapeutic Area : Musculoskeletal
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study on Autologous Osteoblastic Cells Implantation in Hypotrophic Non-Union Fractures
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 25, 2012
Lead Product(s) : Autologous Osteoblastic Cell
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
